Clinical trial
Evaluating the Effect of Candesartan vs Placebo in Prevention of…
NCT00459771 · The Netherlands Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00459771 |
|---|---|
| Title | Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity |
| Official title | Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab |
| Lead sponsor | The Netherlands Cancer Institute, Other |
| Collaborators | AstraZeneca Industry Roche Pharma AG |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | AT1 blocker candesartan, Placebo |
| Enrollment | 210 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2014 |
| First posted | Apr 12, 2007 |
| Last update posted | Dec 2, 2014 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: